These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 2236267)

  • 1. Behavioral effects of chronic imipramine treatment in genetically nervous pointer dogs.
    Tancer ME; Stein MB; Bessette BB; Uhde TW
    Physiol Behav; 1990 Jul; 48(1):179-81. PubMed ID: 2236267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychopharmacologic facilitation of operant conditioning of genetically nervous catahoula and pointer dogs.
    Murphree OD; DeLuca DC; Angel C
    Pavlov J Biol Sci; 1974; 9(1):17-24. PubMed ID: 4220360
    [No Abstract]   [Full Text] [Related]  

  • 3. A behavioral and autonomic nervous system study of chronic imipramine administration to conscious dogs.
    Korol B; Yaffe GJ; Biddy RL; Bidus DR
    Pharmacology; 1978; 16(2):61-9. PubMed ID: 619365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of imipramine treatment on the unconditioned alimentary behavior and classical conditioned salivary reactions in dogs.
    Korczyński R; Fonberg E
    Acta Neurobiol Exp (Wars); 1979; 39(3):157-71. PubMed ID: 543461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The rehabilitation of genetically nervous dogs.
    McBryde WC; Murphree OD
    Pavlov J Biol Sci; 1974; 9(2):76-84. PubMed ID: 4220367
    [No Abstract]   [Full Text] [Related]  

  • 6. The effects of imipramine on socio-emotional and alimentary motivated behavior in dogs.
    Zagrodzka J; Korczyński R; Fonberg E
    Acta Neurobiol Exp (Wars); 1981; 41(4):363-72. PubMed ID: 7325016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between genetic deafness and fear-related behaviors in nervous pointer dogs.
    Klein E; Steinberg SA; Weiss SR; Matthews DM; Uhde TW
    Physiol Behav; 1988; 43(3):307-12. PubMed ID: 3174842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in conditioned performance and general behavior produced by imipramine treatment in dogs.
    Fonberg E
    Pol J Pharmacol Pharm; 1979; 31(4):437-50. PubMed ID: 392473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is buspirone effective for panic disorder?
    Sheehan DV; Raj AB; Sheehan KH; Soto S
    J Clin Psychopharmacol; 1990 Feb; 10(1):3-11. PubMed ID: 2407755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fearful behavior, body size, and serum IGF-I levels in nervous and normal pointer dogs.
    Uhde TW; Malloy LC; Slate SO
    Pharmacol Biochem Behav; 1992 Sep; 43(1):263-9. PubMed ID: 1409812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in socio-emotional behavior under imipramine treatment in normal and amygdalo-hypothalamic dogs.
    Kostarczyk E; Fonberg E; Prechtl JC
    Acta Neurobiol Exp (Wars); 1986; 46(4):187-203. PubMed ID: 3788669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversible inactivation of the dorsal raphe nucleus blocked the antipanic-like effect of chronic imipramine in the elevated T-maze.
    Dombrowski PA; Andreatini R
    Neurosci Lett; 2006 Oct; 407(1):80-5. PubMed ID: 16959426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imipramine induced heart failure in the dog: a model to study the effect of cardiac assist devices.
    Lucas CM; Cheriex EC; van der Veen FH; Habets J; van der Nagel T; Penn OC; Wellens HJ
    Cardiovasc Res; 1992 Aug; 26(8):804-9. PubMed ID: 1451156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of pointer dog behavior. Drug effects and neurochemical correlates.
    Angel C; DeLuca DC; Newton JE; Reese WG
    Pavlov J Biol Sci; 1982; 17(2):84-8. PubMed ID: 6891959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic differentiation in pointing dog breeds inferred from microsatellites and mitochondrial DNA sequence.
    Parra D; Méndez S; Cañón J; Dunner S
    Anim Genet; 2008 Feb; 39(1):1-7. PubMed ID: 18254732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Classification and determination of the pharmacodynamics of a new tetracyclic antidepressive agent, pirlindol, using pharmaco-EEG and psychometry].
    Saletu B; Grünberger L; Linzmayer L; Wittek R; Stöhr H
    Wien Klin Wochenschr; 1983 Jul; 95(14):481-93. PubMed ID: 6356628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential sensitivity to morphine in nervous and normal pointer dogs.
    Angel C; McMillan DE; Newton JE; Reese WG
    Eur J Pharmacol; 1983 Aug; 91(4):485-91. PubMed ID: 6617751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative pharmaco-electroencephalographic differentiation between the CNS effects of bromocriptine and imipramine, drugs with qualitatively different antidepressant properties.
    Yamadera H; Ferber G; Matejcek M; Pokorny R
    Pharmacopsychiatry; 1987 Mar; 20(2):54-9. PubMed ID: 3588662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 24-hour motor activity in genetically nervous and normal pointer dogs.
    Klein E; Uhde TW
    Biol Psychiatry; 1988 Mar; 23(5):523-7. PubMed ID: 3345326
    [No Abstract]   [Full Text] [Related]  

  • 20. [The effect of antidepressants of the imipramine group on the higher nervous activity of the dog].
    Sologub NM
    Fiziol Zh; 1972; 18(2):159-67. PubMed ID: 5078057
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.